Acomplia could reach sales of $3 billion per year

Share this article:

Sanofi-Aventis' new obesity drug Acomplia could eventually generate sales of over $3 billion a year, its chairman told Reuters news service yesterday.
"I can tell you that for such a product, in my expectations, three (billion dollars) is not too much," Jean-Francois Dehecq said during a meeting of pharmaceutical executives in Brussels, commenting on forecasts for the medicine.
Sanofi-Aventis anticipates the launch of Acomplia, which also helps people quit smoking, to take place in the first part of 2006.
The drug is among the world's most anticipated since a global obesity epidemic threatens the health of millions of people in developed countries.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.